Librela (bedinvetmab) Injection for Dogs

Librela (bedinvetmab) Injection for Dogs - Image 2

Librela (bedinvetmab) Injection for Dogs - Image 3

Librela (bedinvetmab) Injection for Dogs - Image 4

Librela (bedinvetmab) Injection for Dogs - Image 5

Librela (bedinvetmab) Injection for Dogs - Image 6

Librela (bedinvetmab) Injection for Dogs - Image 7

Librela (bedinvetmab) Injection for Dogs - Image 8

Librela (bedinvetmab) Injection for Dogs - Image 9

Librela (bedinvetmab) Injection for Dogs

Name: Librela (bedinvetmab) Injection for Dogs
Brand: Librela
SKU: 64443
Availability: InStock
Rating: 4.25 (4 reviews)

Price range: $ 52.99 through $ 94.99

Rated 4.25 out of 5 based on 4 customer ratings

(4 customer reviews)

Prescription(s) Required

We’ll collect your pet information to verify this prescription with your veterinarian before shipping. Your prescription order will ship upon veterinarian approval.

This item is specially packaged to remain refrigerated during transit. 1-2 Day Air Refrigerated Shipping Only OR Local Pickup. Does not Qualify for Free Shipping.

STRENGTH/SIZE

PACKAGING

Clear

Categories: Dog Anti-inflammatory, Dog Arthritis/Pain, Dog Pain Tag: Anti-inflammatory Brand: Librela Brand: Librela

Description

Description
Canine osteoarthritis (OA) is both a common and chronic condition that many dogs are diagnosed with. Librela is a monoclonal antibody. Librela is the first and only monthly injectable monoclonal antibody therapy for dogs with osteoarthritis (OA) pain. Librela works as a potent inhibitor of canine NGF activity, a key OA pain mediator, thus reducing canine OA pain.

Approved as safe and effective and provides long-term canine OA pain control
A monthly subcutaneous injection, administered at the clinic by veterinary professionals
Reduced canine OA pain, which led to increased activity and improved quality of life

Uses

LIBRELA is indicated for the control of pain associated with osteoarthritis in dogs.

For more information visit: https://www.zoetisus.com/products/dogs/librela-a-new-era-in-treatment

Additional information

Weight	N/A
STRENGTH/SIZE	5mg (11- 22.1 lbs.), 10mg (22.2- 44.1lbs), 15mg (44.2- 66.1 lbs.), 20mg (66.2- 88.2 lbs.), 30mg (88.3- 132.3 lbs.)
PACKAGING	1 Vial
Brand	Librela
DOSAGE AND ADMINISTRATION	The minimum target dose of LIBRELA is 0.23 mg/lb (0.5 mg/kg) body weight, administered subcutaneously once a month. Dogs should be dosed by weight range according to the specific dosing information below. The product does not contain a preservative. The full content of each vial is for single-use only. Once punctured, contents of the vial should be used immediately and any remaining solution should be discarded.
CONTRAINDICATIONS	LIBRELA should not be administered to dogs with known hypersensitivity to bedinvetmab. LIBRELA should not be used in breeding dogs or in pregnant or lactating dogs. Immunoglobulin G class antibodies such as LIBRELA can pass through the placental blood barrier and be excreted in milk. Fetal abnormalities, increased rates of stillbirths and increased postpartum fetal mortality were noted in rodents and primates receiving anti-NGF monoclonal antibodies.
WARNINGS	User Safety Warnings Not for use in humans. Keep this and all drugs out of reach of children. For use in dogs only. Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet, vial or carton to the physician. Pregnant women, women trying to conceive, and breastfeeding women should take extreme care to avoid accidental self-injection. The importance of Nerve Growth Factor in ensuring normal fetal nervous system development is well-established and laboratory studies conducted on nonhuman primates with human anti-NGF antibodies have shown evidence of reproductive and developmental toxicity.
PRECAUTIONS	Administration of monoclonal antibodies may be associated with hypersensitivity reactions and delayed hypersensitivity reactions. If anaphylaxis or other hypersensitivity reaction occurs, discontinue use and institute appropriate therapy. The safe use of this product with other monoclonal antibodies has not been evaluated. Use with caution in dogs with known hypersensitivity to other immunoglobulin therapy. Evaluations were not made to determine if interactions occurred between LIBRELA and veterinary vaccines. Treatment with LIBRELA may result in the formation of anti-bedinvetmab antibodies and potentially the loss of product effectiveness (see IMMUNOGENICITY). The safe use of anti-NGF monoclonal antibodies with concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) has not been established in dogs. In human clinical trials, rapidly progressing osteoarthritis (RPOA) has been reported in a small number of patients receiving humanized anti-NGF monoclonal antibody therapy. The incidence of these events increased in human patients receiving NSAID treatment long term in combination with an anti-NGF monoclonal antibody. RPOA has not been characterized or reported in dogs. The safety and effectiveness of LIBRELA has not been evaluated in dogs less than 12 months of age. LIBRELA has not been studied in dogs that have a history of cruciate ligament rupture within six months before initial product use as these cases were excluded from the field studies. Long term effects which may occur more than 9 months after the use of LIBRELA have not been evaluated. NGF is expressed within the heart and vasculature, and the long-term effects of reduced NGF in dogs with cardiac disease are unknown. Primates receiving high doses of anti-NGF monoclonal antibodies had anatomical changes in postganglionic cell bodies (reduced size and number of neurons). The change in cell body size returned to normal after anti-NGF monoclonal antibody administration was discontinued. NGF is involved in the normal development of sensory and sympathetic nerve fibers in developing animals. This may be important with use of LIBRELA in young growing dogs.
ADVERSE REACTIONS	The safety of LIBRELA was assessed in a masked, controlled 84-day US field study evaluating the effectiveness of LIBRELA for the control of pain associated with osteoarthritis. Enrollment included 272 dogs, 135 dogs treated with LIBRELA and 137 dogs treated with a negative control (sterile saline). The enrolled dogs were at least 1 year of age (1 to 17 years old), weighed between 1.8 to 62.7 kg and were of various breeds or non-purebred. Dogs were dosed at 28-day intervals and received up to three injections. The most common adverse reactions reported during the study are summarized here: Urinary tract infection, Bacterial skin infection, Dermatitis, Dermal mass, Erythema, Dermal cyst(s), Pain on injection, Inappropriate urination, Histiocytoma,
STORAGE CONDITIONS	LIBRELA (bedinvetmab injection) should be stored in a refrigerator, 2° – 8°C (36° – 46° F). Do not freeze. Store vials in their boxes to protect from prolonged exposure to light. Once punctured, contents of the vial should be used immediately and any remaining solution should be discarded.

4 reviews for Librela (bedinvetmab) Injection for Dogs

4.3

Based on 4 reviews

5 star	75	75%
4 star		0%
3 star		0%
2 star	25	25%
1 star		0%

1-4 of 4 reviews

Debra Falkenstein
Verified owner

08/20/2025

Verified review - view original
I believe my dog is not getting better like before.

(0) (0)
Richard L.
Verified owner

07/02/2025

Verified review - view original
The cost of the medication was 35% less than had I purchased it from my vet. Anyone can easily learn how to give Librela subcutaneously into the scruff of their dog’s neck.

(0) (0)
Cheryl DeHaven
Verified owner

05/05/2025

Great price awesome customer service and speedy delivery
I recommend 0

(0) (0)
Cheryl DeHaven
Verified owner

05/05/2025

Great prices awesome customer service and speedy delivery
I recommend 0

(0) (0)